Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors

被引:506
作者
Kutner, Robert H. [1 ]
Zhang, Xian-Yang [1 ]
Reiser, Jakob [1 ,2 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Med, Gene Therapy Program, New Orleans, LA 70112 USA
[2] US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Rockville, MD 20852 USA
关键词
VESICULAR STOMATITIS-VIRUS; MESENCHYMAL STEM-CELLS; NONDIVIDING CELLS; GENE-TRANSFER; ENVELOPE GLYCOPROTEINS; TRANSGENE EXPRESSION; TRANSDUCTION; TITER; PROMOTERS; GENERATION;
D O I
10.1038/nprot.2009.22
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Over the past decade, lentiviral vectors have emerged as powerful tools for transgene delivery. The use of lentiviral vectors has become commonplace and applications in the fields of neuroscience, hematology, developmental biology, stem cell biology and transgenesis are rapidly emerging. Also, lentiviral vectors are at present being explored in the context of human clinical trials. Here we describe improved protocols to generate highly concentrated lentiviral vector pseudotypes involving different envelope glycoproteins. In this protocol, vector stocks are prepared by transient transfection using standard cell culture media or serum-free media. Such stocks are then concentrated by ultracentrifugation and/or ion exchange chromatography, or by precipitation using polyethylene glycol 6000, resulting in vector titers of up to 10(10) transducing units per milliliter and above. We also provide reliable real-time PCR protocols to titrate lentiviral vectors based on proviral DNA copies present in genomic DNA extracted from transduced cells or on vector RNA. These production/concentration methods result in high-titer vector preparations that show reduced toxicity compared with lentiviral vectors produced using standard protocols involving ultracentrifugation-based methods. The vector production and titration protocol described here can be completed within 8 d.
引用
收藏
页码:495 / 505
页数:11
相关论文
共 26 条
[1]   High-efficiency gene transfer into CD34(+) cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G [J].
Akkina, RK ;
Walton, RM ;
Chen, ML ;
Li, QX ;
Planelles, V ;
Chen, ISY .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2581-2585
[2]   Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters [J].
Amendola, M ;
Venneri, MA ;
Biffi, A ;
Vigna, E ;
Naldini, L .
NATURE BIOTECHNOLOGY, 2005, 23 (01) :108-116
[3]   Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain [J].
Baekelandt, V ;
Eggermont, K ;
Michiels, M ;
Nuttin, B ;
Debyser, Z .
GENE THERAPY, 2003, 10 (23) :1933-1940
[4]   Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system [J].
Chen, ST ;
Iida, A ;
Guo, L ;
Friedmann, T ;
Yee, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (19) :10057-10062
[5]   Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis [J].
Cornu, TI ;
de la Torre, JC .
JOURNAL OF VIROLOGY, 2002, 76 (13) :6678-6688
[6]   Altering the tropism of lentiviral vectors through pseudotyping [J].
Cronin, J ;
Zhang, XY ;
Reiser, J .
CURRENT GENE THERAPY, 2005, 5 (04) :387-398
[7]  
Follenzi A, 2002, METHOD ENZYMOL, V346, P454
[8]   A comparative analysis of constitutive and cell-specific promoters in the adult mouse hippocampus using lentivirus vector-mediated gene transfer [J].
Kuroda, Hitoshi ;
Kutner, Robert H. ;
Bazan, Nicolas G. ;
Reiser, Jakob .
JOURNAL OF GENE MEDICINE, 2008, 10 (11) :1163-1175
[9]   Factors influencing the titer and infectivity of lentiviral vectors [J].
Logan, AC ;
Nightingale, SJ ;
Haas, DL ;
Cho, GJ ;
Pepper, KA ;
Kohn, DB .
HUMAN GENE THERAPY, 2004, 15 (10) :976-988
[10]  
MARINO MP, 2003, LENTIVIRUS GENE ENG, V229, P43